Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

DMX 942
August 11th, 2023

Dimerix in Partnering Discussions, Interim Results out March 2024

Dimerix (DXB) CEO Nina Webster had encouraging news to share regarding the status of DXB's ACTION3 trial at the 17th annual Bioshares Biotech Summit. The pivotal Phase III trial is a randomised, double-blind, placebo-controlled trial of the efficacy and safety of DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS), a rare form of kidney disease.

NEUREN 941
July 21st, 2023

Neuren Pharmaceuticals Moves to Worldwide License for Trofinetide and NNZ-2591 with Acadia

Neuren Pharmaceuticals (NEU: $14.20) announced this week a significant expansion of its partnership with US biopharmaceutical company Acadia Pharmaceuticals (NASDAQ: ACAD). The agreement not only sees Acadia's exclusive licence for trofinetide in North America expand to a worldwide licence, but also Acadia's acquisition of the exclusive worldwide licence for NNZ-2591 in Rett Syndrome and Fragile X Syndrome.

pharmaxis 939
June 6th, 2023

Mixed Results from Pharmaxis' Scar Treatment Study

Pharmaxis (PXS: $0.048) recently wrapped up its PXS-6302 Solaria 2 Trial, showing "encouraging" results. The double-blind placebo-controlled study followed 42 adult patients with an established scar (>1 year old) for three months. Patients were treated with PXS-6302 with the collagen content of scarred skin assessed using biopsy. Patient and Observer Scar Assessment Scale (POSAS) measurements were also taken for both experimental and control groups before and after the course of treatment.

ebr systems 2
June 6th, 2023

EBR Systems Achieves Positive Results in Pivotal Study

EBR Systems (EBR: $1.12) is developing the world's first wireless pacing system for the left ventricle of the heart. The company recently announced positive clinical results from its pivotal US study which opens the path for FDA registration of the device.

immuron 938
May 19th, 2023

Immuron Receives FDA Clearance for Third US Study

The FDA has removed a clinical hold on Immuron's (IMC: $0.08) study for a new therapeutic to prevent infectious diarrhea, caused by two bacteria, E. coli and Campylobacter.

EBR SYSTEMS 1905 EDITION
May 19th, 2023

EBR Systems Pivotal Trial Results to be Announced this Week

The results from EBR Systems'(EBR: $0.905) pivotal study will be presented at the Heart Rhythm 2023 meeting this weekend. EBR is holding a webinar this Monday morning to discuss the results.

Dimerixlogocolour3x
May 19th, 2023

Dimerix to Raise $12 Million in Difficult Market

Dimerix (DXB: $0.072) is seeking to raise $12 million at $0.08 per share. Confirming the difficult capital markets, the raise will include a rights issue and also convertible note financing.

CHM 938
May 19th, 2023

Chimeric Therapeutics Opens $6.3 Million Capital Raise

Chimeric Therapeutics (CHM: $0.039) has announced a capital raise for up to $6.3 million, which comprises of a $1.04 million placement to board and management and a $5.25 million SPP.

anteris
May 19th, 2023

Anteris Technologies - Expands Programs to Mitral and Tricuspid Valve Repair

Anteris Technologies (AVR: $23.00) finished the March quarter with $32 million in cash following a $35 million capital raise in the quarter at $24 per share. The company's net cash outflow for the last three quarters from operational and investment activities was $14.5 million.

cogstate
May 19th, 2023

Cogstate - Eli Lilly's Donanemab Confirms Benefit of Beta Amyloid Drugs for Alzheimer's

Eli Lilly has achieved unequivocally positive efficacy outcomes from its Phase III study with the drug candidate donanemab for the treatment of early stage Alzheimer's disease. It's the second positive late stage study result in the last year, with Eisai & Co achieving similarly positive results with its drug Leqembi (lecanemab).

Pages